http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019510075-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 |
| filingDate | 2017-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2019510075-A |
| titleOfInvention | Composition for treating or preventing liver cancer |
| abstract | This application includes the compound 5-fluoro-3-phenyl-2-[(1S) -1- (7H-purin-6-ylamino) propyl] -4 (3H) -quinazolinone, a pharmaceutically acceptable salt thereof. The present invention relates to a pharmaceutical composition for the prevention and treatment of liver cancer, wherein the composition of the present application inhibits ROS-PI3K-AKT-TERT signaling, thereby overexpressing the protein involved in signaling, In particular, it can be usefully used for the treatment of advanced hepatocellular carcinoma. |
| priorityDate | 2016-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 251.